Managed Account Advisors’s Pacira BioSciences PCRX Stock Holding History

Managed Account Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$16.7M	Sell	236,330 -25,778	-10%	-$2.03M	0.01%	801
2015 Q1	$23.3M	Buy	262,108 +74,773	+40%	+$7.59M	0.02%	654
2014 Q4	$16.6M	Buy	187,335 +28,922	+18%	+$2.74M	0.02%	792
2014 Q3	$15.4M	Buy	158,413 +111,325	+236%	+$10.8M	0.02%	801
2014 Q2	$4.33M	Buy	47,088 +8,027	+21%	+$611K	0.01%	1446
2014 Q1	$2.73M	Buy	39,061 +5,066	+15%	+$345K	﹤0.01%	1617
2013 Q4	$1.95M	Buy	33,995 +33,726	+12,538%	+$1.77M	﹤0.01%	1725
2013 Q3	$13K	Buy	+269	New	+$9.8K	﹤0.01%	2422

Other funds holding PCRX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCM

Marsico Capital Management Denver, Colorado $3.83B AUM 63.68% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Managed Account Advisors's PCRX Position: Q2 2015 in Review

Managed Account Advisors reduced its Pacira BioSciences (PCRX) stake by 9.8% in Q2 2015, selling an estimated $2.03M and leaving 236,330 shares worth $16.7M. The position accounts for 0.01% of the portfolio, ranked #801.

Managed Account Advisors first reported a position in PCRX in Q3 2013 and has held it in 8 quarters since. The position peaked at $23.3M in Q1 2015. 187 funds tracked by Wall St. Rank hold PCRX as of Q2 2015.

Managed Account Advisors held 236,330 shares of Pacira BioSciences worth $16.7M as of Q2 2015.
Managed Account Advisors sold 25,778 Pacira BioSciences shares in Q2 2015, an estimated $2.03M.
Pacira BioSciences made up 0.01% of Managed Account Advisors's portfolio in Q2 2015, its #801 holding.
Managed Account Advisors first reported a position in Pacira BioSciences in Q3 2013 and has held it in 8 quarters since.
Managed Account Advisors's Pacira BioSciences position peaked at $23.3M in Q1 2015.
187 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.